Trials / Completed
CompletedNCT01353092
Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression
PEMF Treatment in Patients With Treatment Resistant Depression in On-going Antidepressant Drug Therapy. A Randomized, Double-blind, Clinically Controlled, Dose-response PEMF Trial for a Duration of Eight Weeks
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Hillerod Hospital, Denmark · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
In this study patients with treatment resistant depression, as defined by Harold Sackeim, is subjected to daily sessions, for eight weeks, with Pulsating ElectroMagnetive Treatment (PEMF). Treatment is given two times a day, in the morning and in the afternoon. Patients are randomized into two groups. In group A patients receive active treatment both morning and afternoon. In group B patients receive one sham and one active treatment. The study is double-blind as neither the assessors or patients are aware of treatment allocation. Each session lasts 30 minutes. Patients are psychometrically assessed weekly for depression severity and side effect. After this intervention period patients are followed for further three weeks without PEMF treatment. Patients are on unchanged medication for the whole of the study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Re5 Pulsating ElectroMagnetic Fields | Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF): 30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon |
| DEVICE | Re5 Pulsating ElectroMagnetic Fields (PEMF) | Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF): 30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon) |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2011-05-12
- Last updated
- 2015-08-26
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01353092. Inclusion in this directory is not an endorsement.